Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas
|
|
- Michael Beasley
- 5 years ago
- Views:
Transcription
1 Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Eyal Leshem December 9, 2013 National Center for Immunization & Respiratory Diseases Division of Viral Diseases
2 Objectives What have we learned about the ecology rotavirus strains after vaccine introduction? What critical questions remain unanswered? How can we answer these questions utilizing rotavirus surveillance? Protocol modifications
3 Rotavirus Strain Typing
4 Rotavirus Strain Typing Rotavirus genomes can recombine through genetic reassortment (like flu virus)
5 Surveillance Before Rotavirus Vaccine Introduction What is rotavirus strain distribution? Match with vaccine antigens
6 Pre-vaccine Rotavirus Strains, G1P8 G2P4 G3P8 G4P8 G9P8 Number of samples = 73,811 Banyai Vaccine 2012
7 Post-vaccine Rotavirus Strains, G3P8 8% G4P8 2% G9P8 9% G1P8 29% G2P4 52% Number of samples = % Brazil 22% US 24% Australia Leshem, Unpublished
8 Post Vaccine Strain Distribution Strain distribution changed Are observed changes related to vaccine introduction or just natural variation over time?
9 Rotavirus Vaccines Rotarix (RV1) Human Rotavirus G1P[8] RotaTeq (RV5) Human-Bovine WC3 Rotavirus Reassortant G1,G2,G3,G4,P[8]
10 Efficacy Against Heterotypic Strains G2P4? G3P8? Rotarix (RV1) Human Rotavirus G1P[8] RotaTeq (RV5) Human-Bovine WC3 Rotavirus Reassortant G1,G2,G3,G4,P[8]
11 Rotavirus Genotyping Results from NVSN 2006 to 2008 Strain Prevalence: 2006 (n=225) G1 P[4] 0.4% G2 P[4] 4.9% G2 P[8] 0.4% G9 P[6] 0.4% G12 P[8] 0.4% G12 P[6] 3.6% GM P[8] 0.9% Strain Prevalence: (n=28) G1 P[6] 1.8% G1 P[M] 3.1% G1 P[8] 84.0% GNT P[NT] 7.1% Strain Prevalence: (n=273) G12 P[M] 0.4% GM P[8] 1.5% GM P[M] 0.4% GNT P[8] 1.1% GNT P[NT] 0.4% G3 P[8] 10.7% G1 P[8] 82.1% G9 P[8] 0.4% G4 P[8] 0.4% G12 P[8] 27.5% G1 P[8] 44.7% G1 P[M] 0.4% G3 P[8] 2.2% G2 P[M] 1.1% G2 P[8] 7.7% G2 P[6] 0.7% G2 P[4] 10.3% G1 P[NT] 1.1% Bowen, CDC
12 Genotype Prevalence USA, NVSN n= Bowen, Unpublished
13 Strains by Year and Vaccine, Australia, RV1 100% 50% 0% N= G9P8 G4P8 G3P9 G2P4 G1P8 RV5 100% 50% 0% N= G9P8 G4P8 G3P9 G2P4 G1P8 Leshem, Unpublished
14 Strains by Vaccine, Australia, G4P8, 5% G3P8, 13% G9P8, 2% G1P8, 32% G4P8, 1% G3P8, 7% G9P8, 7% G1P8, 37% G2P4, 48% G2P4, 48% RV5 N=519 RV1 N=769 Leshem, Unpublished
15 Conclusion 1: Post Vaccine Strain Distribution Changes in strain distribution: Do not appear to be consistent over several years No particular patters is associated with either vaccine
16 Post Vaccine Strain Distribution How effective are rotavirus vaccines against specific strains in real life? Vaccine status Age Severity
17 RV1 Strain Specific Effectiveness Middle Income Countries Author/Year Country Strain Vaccine Effectiveness (95% CI) De Palma 2010 El Salvador* G1P8 (92%) 76% (64,84) Gurgel 2009 Brazil G2P4 89% (87,92) Corriera 2010** Brazil G2P4 77% (43,90) Justino 2011 Brazil G2P4 75% (57,86) Patel 2013 Bolivia* G2P4 71% (19,90) Patel 2013 Bolivia* G3P8 92% (60,98) Yen 2011 Mexico G9P4 94% (16,100) Patel 2013 Bolivia* G9P6 87% (-10,98) Patel 2013 Bolivia* G9P8 84% (64,92) *Low middle income ** 6-11 month olds Leshem, Unpublished
18 RV5 Genotype-Specific Vaccine Effectiveness NVSN Data, % VE Payne Clin Infect Dis 2013
19 Conclusion 2: Vaccine Effectiveness All data indicate good heterotypic protection from vaccines to date
20 Additional Questions Significance of events detected by surveillance: Outbreaks Rotavirus affecting older children, adults and elderly Circulating vaccine reassontant strains Circulating animal related strains Non-typeable strains Vaccine failures
21
22 Rose EID 2013
23 Objectives What have we learned about the ecology rotavirus strains after vaccine introduction? What critical questions remain unanswered? How can we answer these questions utilizing rotavirus surveillance? Protocol modifications
24 Recommendations: Country Rotavirus Surveillance Prioritization of data quality over quantity of samples Emphasis on linkage of strain and epidemiology data Patient age, disease severity, vaccine status Enhanced surveillance sites
25 Recommendations: Country Rotavirus Surveillance Capacity building in country rotavirus reference laboratories G,P Strain typing Specimen archive What proportion of cases do we need to save and genotype?
26 Recommendations: Regional Reference Laboratory Support country rotavirus surveillance Training and capacity building Quality assurance, resolution of problems
27 Recommendations: Regional Reference Laboratory Hypothesis driven research Strain characterization by advanced molecular techniques: Emerging; outbreak; vaccine reassortant; animal related; non-typeable; vaccine failures Characterize vaccine failures detect co-infection with other diarrheal pathogens
28 Recommendations: Regional Reference Laboratory Hypothesis driven research Serologic studies: waning immunity; population studies Studies of rotavirus circulation in older children, adult and elderly
29 Conclusion
30 Conclusion
31 Acknowledgments Roger Glass NIH Dioselina Pelaez Instituto Nacional de Colombia Michael Bowen CDC Martha Elizabeth Melendez Quevedo Laboratorio Nacional de Referencia MOH El Salvador Duncan Steele BMGF Dina Castro Laboratorio Nacional de Virologia Honduras John Gentsh CDC Herlinda Garcia Lozano Jose Paulo Leite Oswaldo Cruz Institute-FIOCRUZ Brazil Instituto Evandro Chagas, MOH Brazil Fatima Serhan Instituto de Diagnotico de Referencia Mexico WHO Alexandre da Costa Linhares Gloria Rey-Benito PAHO - Costa Rica Manish Patel CDC Lúcia de Oliveira PAHO - WDC Cuauhtemoc Ruiz PAHO - WDC Jennifer Sanwogou PAHO - WDC Matus
32 Discussion Points Improving data linking epi and lab Case sensitive ID numbers Vaccine data photocopy of vaccine card Improving timeliness and quality of data at all levels Challenges of sentinel, national and regional laboratories Ensure compliance with rules and responsibilities of sentinel laboratories Improve communication and feedback between actors in sentinel surveillance
33 Summary Rotavirus Surveillance Before Introduction Question What is strain distribution? Data collected Strains After introduction How does strain distribution change? What is the impact of strain changes on vaccine effectiveness? How to interpret detection of unusual strains? Strains Vaccine status Age Clinical severity (hospitalized?)
34 RV1 Proportion of samples by strain and year, post rotavirus vaccine introduction, published worldwide, % 50% 0% N= G9P8 G4P8 G3P9 G2P4 G1P8 RV5 100% 50% 0% G9P8 G4P8 G3P9 G2P4 G1P8 N=
35 Visits / 10,000 PY Diarrhea-Associated Hospitalizations Vaccinated Vs. Unvaccinated Children<5, US, Rotavirus-Coded 0.4 Unvaccinated RV5 RV1
36 Visits / 10,000 PY Diarrhea-Associated Hospitalizations Vaccinated Vs. Unvaccinated Children<5, US, RV5 92% (87-96) RV1 96% (74-100) 1 Rotavirus-Coded 0.4 Unvaccinated RV5 RV1
37 Visits / 10,000 PY Diarrhea-Associated Hospitalizations Vaccinated Vs. Unvaccinated Children<5, US, Unvaccinated RV5 RV Any-Diarrhea
38 Visits / 10,000 PY Diarrhea-Associated Hospitalizations Vaccinated Vs. Unvaccinated Children<5, US, RV5 55% (46-62) RV1 53% (36-66) Unvaccinated RV5 RV Any-Diarrhea
39 Visits / 10,000 PY Diarrhea-Associated Hospitalizations Children<5, United States RV All diarrhea Rotavirus-coded diarrhea Leshem, Unpublished
40 Real-World Decline in Childhood Diarrhea Deaths after Rotavirus Vaccination in Mexico Vaccine Introduction (May 2007) 2011 *Gastanaduy Pediatrics
41 Reduction % RV5 Provided Good Efficacy against Common Rotavirus Strains 0 % G1 G2 G3 G4 G9 100% 95% CI 95%* [92,97] 88% [<0,99] 93%[ 49,99] 89%* [52,98] 100%* [67,100] Vesikari NEJM
42 Vaccine efficacy (%) RV1: Potential lower efficacy against G2P[4] strains in Latin America 92% G1 P[8] 91% 88% In Europe, efficacy against G2P4 was 86% 41 [-79.2; 82.4] G9 P[8] G3 P[8] G2 P[4] Ruiz-Palacios NEJM 2006
Monitoring For Rotavirus Serotypes In The Americas. Jon Gentsch
Monitoring For Rotavirus Serotypes In The Americas Jon Gentsch Centers for Disease Control and Prevention, Atlanta, USA * The findings and conclusions in this presentation are those of the authors and
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationUsing surveillance data to monitor impact of rotavirus vaccine. Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO
Using surveillance data to monitor impact of rotavirus vaccine Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO Main Topics Epidemiological surveillance of rotavirus in American Region Impact
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationRotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia
Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia Lucia Inchauste, Nataniel Mamani, Sonia Jimenez, Raul Montesano, Maritza Patzi, Rita Revollo,
More informationRotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore
Rotavirus Vaccines Gagandeep Kang Christian Medical College Vellore Rotavirus disease burden Rotavirus vaccines and candidates Performance of vaccines in developed and developing countries Longitudinal
More informationRotavirus vaccine impact
Rotavirus vaccine impact Introduction. Rotavirus vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated children Rotavirus vaccines are saving lives and
More informationDr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine
Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and
More informationProgress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere,
1 Introduction: Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 2003-2008 1 Enhanced measles elimination activities in the Region of the Americas during the
More informationDr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director
ROTARIX the human rotavirus vaccine: -is applied in a 2-dose schedulecompletes the course at the earliest possible age, prevents morbidity and mortality from RV GE regardless of the circulating strains
More informationREVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward
REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward SARInet annual meeting, Punta Cana, May 23 2017 Nathalie El Omeiri On behalf of REVELAC-i network, Alba
More informationInfluenza Vaccine Use In the Americas
Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i Alba Maria Ropero-Alvarez Comprehensive Family Immunization Unit PAHO/FGL/IM Global Vaccine and
More informationRotavirus: WHO Global Recommendations, Policy, and Surveillance
Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:
More informationAssessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination
Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationRubella and CRS Elimination in the Americas
Rubella and CRS Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February 2012 Presentation Opportunities for a rubella elimimation initiative The impact of the initiative
More informationEdwin J. Asturias Associate Director
Edwin J. Asturias Associate Director Center for Global Health Associate Professor of Pediatrics and Epidemiology Effectiveness Dengue Vaccine Washington DC, June 2014 UNIVERSITY OF COLORADO COLORADO STATE
More informationIntroduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI
Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making
More informationAlternative Rotavirus Vaccine Candidates: Why should we bother?
Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines
More informationApproaches to Assessing Intussusception Risk in Developing Countries
Approaches to Assessing Intussusception Risk in Developing Countries Jacqueline Tate Centers for Disease Control and Prevention Atlanta, GA, USA National Center for Immunization & Respiratory Diseases
More informationCan we improve the performance of live oral rotavirus vaccines?
Can we improve the performance of live oral rotavirus vaccines? Duncan Steele 9 th International Rotavirus Symposium 2 & 3 August 2010, Johannesburg, South Africa Vaccine efficacy against severe rotavirus
More informationSustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization
Clinical Infectious Diseases SUPPLEMENT ARTICLE Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization Edgar Sánchez-Uribe,
More informationPandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators
Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated
More informationStrengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative
http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November
More informationRegional Update EW 41 Influenza (October 25, h GMT; 12 h EST)
Regional Update EW 41 Influenza (October 2, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationRegional Update Influenza (August 16, h GMT; 12 h EST)
Regional Update Influenza (August 16, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationEffect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico
original article Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico Vesta Richardson, M.D., Joselito Hernandez-Pichardo, M.D., Manjari Quintanar-Solares, M.D., Marcelino Esparza-Aguilar,
More informationRoger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research, NIH
Rotavirus Vaccines: Prioritization for Introductions- National & International Case Studies Fondation Merieux Conference Center November 27, 2012 Roger I. Glass, M.D., Ph.D. Director, Fogarty International
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationA NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT. Introducing the Gates Medical Research Institute
A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research Institute MY JOURNEY A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research
More informationUS Rotavirus Vaccination Program
US Rotavirus Vaccination Program 1 Rotavirus Vaccines in US Feb 2006 Feb 2006 April 2008 June 2008 RotaTeq licensed by FDA RotaTeq recommended by ACIP Rotarix licensed by FDA ACIP to consider Rotarix 2
More informationPopulation effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies
Hungerford et al BMC Infectious Diseases (2017) 17:569 DOI 101186/s12879-017-2613-4 RESEARCH ARTICLE Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and
More informationRSV Surveillance in the U.S.
RSV Surveillance in the U.S. Susan I. Gerber, MD Respiratory Virus Program Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention
More informationCase study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan
15 th ADVAC Case study Rota in Sudan Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan Background Rotavirus is one
More information20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.
B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationHepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
More informationRotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation
SUPPLEMENT ARTICLE Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation A. Duncan Steele, 1,2 Manish Patel,
More informationReport of the Regulatory Forum on Update on Clinical Experience with Rotavirus Vaccines
Report of the Regulatory Forum on Update on Clinical Experience with Rotavirus Vaccines Held during the Sixth Meeting of the Developing Countries Vaccine Regulator's Network (DCVRN) 23 May 2007 Brasilia,
More informationA Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationPandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators
Regional Update Pandemic (H1N1) 2009 (August 14, 2009-17 h GMT; 12 h EST) Update on the Qualitative Indicators For epidemiological week 31 (EW 31, August 2 to August 8) 17 countries have reported updated
More informationRegional Update EW 30 Influenza (August 9, h GMT; 12 h EST)
Regional Update EW 30 Influenza (August 9, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: HUhttp://new.paho.org/hq/index.php?option=com_content&task=view&id=3352&Itemid=2469&to=2246U
More informationDoes Rota Vaccine Reduce Attacks of Acute Gastroenteritis among Children Under 15 Months of Age?
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1178-1184 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.142
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationRegional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (May 24, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationLessons from Rotavirus Vaccine Implementation in the U.S.
Lessons from Rotavirus Vaccine Implementation in the U.S. Jeff Duchin, MD Chief, Communicable Disease Epidemiology & Immunization Section Public Health - Seattle & King County Professor in Medicine, Division
More informationChanges in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program
Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program Rotavirus gastroenteritis is the leading cause of severe acute gastroenteritis (AGE)
More informationRotavirus and Rotavirus Vaccines
Proceedings of the Seventh International Symposium June 12 13, 2006 Lisbon, Portugal Rotavirus and Rotavirus Vaccines Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations
More informationRegional Update EW 44 Influenza (November 16, h GMT; 12 h EST)
Regional Update EW 44 Influenza (November 16, 21-17 h GMT; 12 h EST) The information presented in this update is summarized based on data provided by Ministries of Health and National Influenza Centers
More informationSenior Management Team Meeting Target setting in Latin America
Senior Management Team Meeting Target setting in Latin America October 2006 Nancy Andrade-Castro RST Latin America Geneva/2006 For all enquiries, please contact Nancy Andrade-Castro, Acting Director for
More informationEXECUTIVE SUMMARY MEETING REPORT
EXECUTIVE SUMMARY MEETING REPORT WHO-Coordinated Rotavirus Surveillance Network Laboratory Technical Working Group Meeting 17-18 November 2014 Rio De Janeiro, Brazil Hotel Marina Palace Meeting Report
More informationRegional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationViral Agents of Paediatric Gastroenteritis
Viral Agents of Paediatric Gastroenteritis Dr Carl Kirkwood -------------------- Enteric Virus Research Group Murdoch Childrens Research Institute Royal Children s Hospital Victoria. WHO Collaborating
More informationIntroduction to the ProVac Initiative
Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of
More informationROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE [ ] THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS
ROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE [ ] THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS ROTACOUNCIL.ORG Table of contents Introduction...4 What is rotavirus?... 5 Vaccines:
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More informationRegional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 29 (July 6, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationRegional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 9 (July 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More information_flu.asp. States. North. The Caribbean and (Cuba, South. South. B was observed.
North America: Influenza activity remained low in the sub-region with co-circulation of influenza A(H1N1)pdm09, A(H3N2) and influenza B. In the United States, no new humann infections with influenza A(H3N2)
More informationFecal shedding of rotavirus vaccine in premature babies in the neonatal unit
Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported
More informationA Briefing Paper on Rotavirus
COMMON VIRUS AND SENSELESS KILLER: A Briefing Paper on Rotavirus DIARRHEA KILLS. MOTHERS IN THE WORLD S POOREST COUNTRIES KNOW THIS ALL TOO WELL. It s a fact few people in wealthier nations realize. Rotavirus
More informationROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS
ROTAVIRUS COMMON, SEVERE, DEVASTATING, PREVENTABLE THE LATEST EVIDENCE & WHAT S NEEDED TO STOP ILLNESSES AND DEATHS 1 Contents I. Executive summary [Slide 3] II. Rotavirus: Background, illnesses and deaths
More information8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM
PROCEEDINGS FROM THE 8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM June 3 4, 2008 Istanbul, Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations for support of the 8th
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationChallenges for Latin America s. Information on Drug Consumption
Challenges for Latin America s Information on Drug Consumption Fatima Marinho, MD, MPH, PHD Coordinator of Information and Health Analysis - PAHO International Day against Drug Abuse & Illicit Trafficking
More informationNew and Underused Vaccines, Rotavirus
New and Underused Vaccines, Rotavirus George Armah Noguchi Memorial Institute for Medical research University of Ghana 10th Annual African Vaccinology Course (VACFA) Cape town, South Africa 10 th to 14
More informationReduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America A Review
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(8): 907-911, December 2011 907 Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin
More informationRoger I. Glass, M.D., Ph.D. Fogarty International Center, NIH Viral Gastroenteritis Unit, CDC
Roger I. Glass, M.D., Ph.D. Fogarty International Center, NIH Viral Gastroenteritis Unit, CDC International Rotavirus Symposia- A 30 year history 1-4. 1984, 1986, 1989, 1991 NIH Bethesda, MD USA 5. 1995
More informationRegional Update EW 46 Influenza (November 28, h GMT; 12 h EST)
Regional Update EW 46 Influenza (November 28, - 17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States
More informationEffectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus
Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Anna Lena Lopez, MD, MPH Director, Institute of Child Health and Human Development,
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationRotavirus Vaccine Impact and Effectiveness in Armenia and Moldova
Rotavirus Vaccine Impact and Effectiveness in Armenia and Moldova Margaret M. Cortese, MD Centers for Disease Control and Prevention 12 th International Rotavirus Symposium, Melbourne, AUST Sept. 7, 2016
More informationCommon Virus and Senseless Killer: A Briefing Paper on Rotavirus
Common Virus and Senseless Killer: A Briefing Paper on Rotavirus Diarrhea kills. Mothers in the world s poorest countries know this all too well. It s a fact few people in wealthier nations realize. Rotavirus
More informationThe Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond
The Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond Max Ciarlet, PhD Vaccines Clinical Research Department Merck Research Laboratories North Wales, Pennsylvania, United
More informationRotavirus is the leading cause of severe diarrhea in
GASTROENTEROLOGY 2009;137:1970 1975 Incidence of Rotavirus and All-Cause Diarrhea in Northeast Brazil Following the Introduction of a National Vaccination Program RICARDO G. GURGEL,*, ANNA K. BOHLAND,*
More informationState of the Art in the Prevention and Control of Dengue in the Americas May, 2014 Washington DC, USA
State of the Art in the Prevention and Control of Dengue in the Americas 28-29 May, 2014 Washington DC, USA Agenda Meeting on the State of the Art for the prevention and control of dengue in the Americas
More informationEffectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases
TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness
More informationConsiderations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden
SUPPLEMENT ARTICLE Considerations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden S. A. Al Awaidy, 1 S. Bawikar, 1 S. Al Busaidy, 2 S. Baqiani, 2 I. Al Abedani, 1
More informationRegional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014)
Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014) PAHO interactive influenza data: Uhttp://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports
More informationRotavirus. Rotavirus. Vaccine-Preventable Diseases WHO Vaccine-Preventable Diseases Surveillance Standards. Surveillance Standards
Last updated: September 5, 2018 Vaccine-Preventable Diseases Surveillance Standards 1 DISEASE AND VACCINE CHARACTERISTICS, a member of the reovirus family, causes watery diarrhoea, vomiting and severe
More informationRegional Update EW 09 Influenza (March 15, h GMT; 12 h EST)
Regional Update EW 09 Influenza (March 15, 2011-17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 18, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 36 (EW 36), from 6 September to 12 September, 17 countries reported
More information*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a
*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a GDPH epidemiologist 404-657-2588, 8-5 pm M-F for current
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Provisional Agenda Item 4.10
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationMarta-Louise Ackers, a Robert E Quick, a Christopher J Drasbek, b Lori Hutwagner c and Robert V Tauxe a
O International Epldemiological Association 998 Printed in Great Britain International Journal of Epidemiology 998:27:-4 Are there national risk factors for epidemic cholera? The correlation between socioeconomic
More informationRESEARCH. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study
1 Ministerio de Salud, San Salvador, El Salvador 2 PanAmerican Health Organization, San Salvador 3 PanAmerican Health Organization, Washington, DC, USA 4 Viral Gastroenteritis Team, Epidemiology Branch,
More informationPrevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti
Prevention of Rotavirus Infections Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Worldwide, Rotavirus Accounted for ~215,000 Childhood Deaths Annually 1 (2000-2013) In children less than 5 years of age:
More informationZika virus (ZIKV) Latin America & Caribbean Situation Report #11 15 February 2017
UNICEF/Ecuador/2016 Zika virus (ZIKV) Latin America & Caribbean Situation Report #11 15 February 2017 UNICEF/LACRO RESPONSE HIGHLIGHTS UNICEF has worked with government and non-government partners to ensure
More informationGeneva, March Consultation background
Consultation on the documentary evidence and independent performance evaluation requirements for the Emergency Use Assessment and Listing procedure for Zika virus in vitro diagnostics Geneva, 14-15 March
More informationPandemic Influenza: Global and Philippine Situation
Pandemic Influenza: Global and Philippine Situation Beatriz Puzon-Quiambao, MD, FPPS, FPIDSP Research Institute for Tropical Medicine 17 th Annual PIDSP Convention, February 3-4, 2010 Chronology of Events
More informationIASR Back Number Vol.35. The Topic of This Month Vol.35 No.3 (No.409) Rotavirus, , Japan. (IASR 35: 63-64, March 2014) Phoca PDF
The Topic of This Month Vol.35 No.3 (No.409) Rotavirus, 2010-2013, Japan (IASR 35: 63-64, March 2014) Rotavirus belongs to the family Reoviridae, whose genome consists of 11 segments of double-stranded
More informationRegional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (December 1, 2009-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More information